SHAREHOLDER ALERT: WeissLaw LLP Investigates Immunomedics, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Immunomedics, Inc. in connection with the proposed acquisition of the Company by Gilead Sciences, Inc. .  Under the terms of the acquisition agreement, which is structured as a tender offer, the Company’s shareholders will receive $88.00 in cash for each share of IMMU common stock that they own.  

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

WeissLaw is investigating whether IMMU’s board acted to maximize shareholder value in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of the proposed acquisition of the Company, and whether all information regarding the valuation of the deal will be fully and fairly disclosed to IMMU shareholders. 

Notably, at least one analyst set a price target of $105.00 per IMMU share, or $17.00 above the per-share offer price.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com